



02 March 2012

Veterinary Medicines and Inspections Unit
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB
United Kingdom

RE: Withdrawal of Paccal Vet (EMEA/V/C/002237)

Applicant: Oasmia Pharmaceutical AB
SME : 011/06

Dear Madam or Sir,

I would like to inform you that Oasmia Pharmaceutical AB has taken the decision to withdraw the application for Marketing Authorisation of Paccal Vet 60 mg lyophilisate for solution for infusion, intended for the treatment of nonresectable grade II or III mast cell tumours in dogs.

This withdrawal is based on the following reason: the CVMP considers that the data provided do not allow the committee to conclude on a positive benefit risk balance.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s)/target species, if applicable. I agree for this letter to be published on the EMEA website.

Sincerely,

A handwritten signature in blue ink, appearing to read "Julian Aleksov". The signature is stylized and includes a long horizontal stroke at the end.

Julian Aleksov
CEO
Oasmia Pharmaceutical AB